The present invention relates to an electrolyte additive including a compound represented by Chemical Formula 1, an electrolyte including the electrolyte additive, and a secondary battery including the electrolyte. Chemical Formula 1:

##STR00001##

R.sub.1 and R.sub.2 are each independently an alkylene group having 1-5 carbon atoms; E.sub.1 is a bond, an alkylene group having 1-3 carbon atoms, or a cyclic carbonyl group, ether group, or ester group having 2-5 carbon atoms; R.sub.3 is a substituted or unsubstituted linear or cyclic carbonate group, carbonyl group, ether group, phosphate group, sulfonate group, or sulfate group having 2-5 carbon atoms; the substitution refers to substitution with one or more selected from F, Cl, Br, and I or an alkenyl group having 1-3 carbon atoms; E.sub.2 is a bond or a saturated or unsaturated alkylene group or ether group having 1-3 carbon atoms; and n is 0 or 1.

Provided are: a nucleating agent composition, which can impart excellent crystallinity to an olefin-based resin and with which a molded article having excellent mechanical properties and transparency can be obtained; an olefin-based resin composition; a molded article of the same; and a method of producing an olefin-based resin composition. The nucleating agent composition contains a nucleating agent and an auxiliary agent. In this nucleating agent composition, the nucleating agent contains an aromatic phosphate metal salt represented by Formula (1) (wherein, R.sup.1 to R.sup.4 each represent an alkyl group having 1 to 6 carbon atoms; R.sup.5 represents a hydrogen atom or an alkyl group having 1 to 3 carbon atoms; n represents 1 or 2; when n is 1, M represents lithium or dihydroxyaluminum; and when n is 2, M represents hydroxyaluminum), the auxiliary agent is at least one selected from the group consisting of water and polyol compounds, and the content of the auxiliary agent is 1 to 10,000 parts by mass with respect to 100 parts by mass of the nucleating agent.

##STR00001##

Provided are: a nucleating agent capable of simultaneously improving the thermal stability and the transparency of a polyolefin resin; a polyolefin-based resin composition containing the same; and a molded article of the composition. The nucleating agent contains a compound represented by Formula (1) below where R.sup.1 to R.sup.4 each independently represent a hydrogen atom or a linear or branched alkyl group having 1 to 9 carbon atoms; R.sup.5 represents an alkanediyl group having 1 to 4 carbon atoms; and M represents a hydrogen atom or a sodium atom. In this nucleating agent, the mass ratio of phosphorus atoms and sodium atoms, P/Na, is in a range of 1.200 to 1.500. ##STR00001##

There are provided compounds of Formula I, and pharmaceutically acceptable salts and esters thereof, and pharmaceutical compositions thereof, used for inhibition or modulation of the activity of cyclin dependent kinases (CDK) and/or glycogen synthase kinase-3 (GSK-3), for the treatment of disease states or conditions mediated by cyclin dependent kinases and/or glycogen synthase kinase-3, including cancers. ##STR00001##

This disclosure relates to uridine diphosphate (UDP) derivatives, compositions comprising therapeutically effective amounts of those UDP derivatives and methods of using those derivatives or compositions in treating disorders that are responsive to ligands, such as agonists, of P.sub.2Y.sub.6 receptor, e.g., neuronal disorders, including neurodegenerative disorders (e.g., Alzheimer's disease) and traumatic CNS injury, as well as pain.

The present disclosure provides compounds that may be used as ligands in metal-catalyzed reactions, in particular 3,3′-bisilyl biaryl phosphoramidite compounds and processes for preparing the same.

Diphosphites having an open, 3-methylated outer unit and use thereof in hydroformylation.

This disclosure relates to the use of uridine diphosphate (UDP) derivatives, salts and/or prodrugs thereof for the treatment of inflammatory conditions (e.g., psoriasis) and glaucoma, to prodrugs of UDP derivatives, compositions comprising therapeutically effective amounts of those prodrugs of the UDP derivatives and methods of using those prodrugs for treating various disorders including, e.g., neuronal disorders, including neurodegenerative disorders (e.g., Alzheimer's disease, Parkinson's disease) and traumatic CNS injury, pain, Down Syndrome (DS), glaucoma, and inflammatory conditions, e.g., psoriasis and rheumatoid arthritis.

Disclosed herein, inter alia, are acyclic nucleotide analogs and methods of using an acyclic nucleotide analog for treating and/or ameliorating a papillomavirus infection.

Diphosphites having an open and a closed 2,4-methylated outer unit and use thereof in hydroformylation.